Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Toxicity Testing in Animals

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Toxicokinetics: Overview

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fetal imaging with microCT (µCT) in the age of AI.

Reproductive toxicology (Elmsford, N.Y.)·2026

Same author

Pharmacokinetics of cannabidiol and its metabolites in rhesus monkeys and New Zealand White rabbits.

Toxicological sciences : an official journal of the Society of Toxicology·2025

Same author

Perspectives on Implementing Virtual Control Groups in Developmental and Reproductive Toxicity Studies.

Birth defects research·2025

Same author

Subdivided Historical Data to Assess Replicability of the Rat Embryo-Fetal Developmental Toxicity Study.

Birth defects research·2025

Same author

The 6Rs of EFDT Studies.

Birth defects research·2024

Same author

The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following <i>in utero</i> opioid exposures in mouse fetuses.

Frontiers in toxicology·2024

Same journal

Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

Same journal

Lost in translation: The search for an in vitro screen for spermatogenic toxicity.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

Same journal

Exposure to high-concentration oxygen in the neonatal period induces abnormal retinal vascular patterning in mice.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

Same journal

Effect of fructose on the phosphorylation of AMP-activated protein kinase and acetyl-CoA carboxylase in HepG2 cells stimulated with placental lactogen.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

Same journal

Reproductive and neurobehavioral effects of maternal exposure to piperonyl butoxide (PBO) in F<sub>1</sub> -generation mice.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

Same journal

Goldilocks' Determination of What New In Vivo Data are "Just Right" for Different Common Drug Development Scenarios, Part 1.

Birth defects research. Part B, Developmental and reproductive toxicology·2016

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Pre- and postnatal developmental toxicity study design for pharmaceuticals.

Graham P Bailey¹, L David Wise, Jochen Buschmann

¹Johnson and Johnson PRD, Janssen Pharmaceutica, Beerse, Belgium. gbailey1@its.jnj.com

Birth Defects Research. Part B, Developmental and Reproductive Toxicology

|December 22, 2009

Summary

This summary is machine-generated.

This study details rodent study designs for assessing pharmaceutical developmental and reproductive toxicity, crucial for drug safety evaluation. It provides guidance on study initiation, duration, and data presentation for regulatory review.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Area of Science:

Pharmacology and Toxicology
Drug Development
Regulatory Science

Background:

Current pharmaceutical toxicity assessment relies on ICH S5(R2) guidelines.
Pre- and postnatal exposure studies primarily use rodent models (rat, mouse).

Purpose of the Study:

To present acceptable study designs for range-finding and definitive toxicity studies.
To provide detailed guidance on data presentation, study initiation, and duration.
To discuss optional parameters and integration with other study designs.

Main Methods:

Utilizing collective author experience to define study protocols.
Describing study initiation and duration relative to clinical timelines.
Outlining data presentation requirements for regulatory submissions.

Main Results:

Established acceptable designs for developmental and reproductive toxicity studies.
Provided clear guidelines for study parameters and scheduling.
Facilitated consistent data interpretation across laboratories.

Conclusions:

The presented details will aid laboratories, study planners, and regulatory agencies.
Standardized study designs enhance the reliability of pharmaceutical safety assessments.
This guidance supports robust evaluation of drug risks during development.